The Conversation (0)
GenSpera Reports Enrollment of First Patient in G-202 Phase II Glioblastoma Trial
Mar. 18, 2014 08:27AM PST
Life Science Investing NewsGenSpera, Inc. (OTCQB:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.
GenSpera, Inc. (OTCMKTS:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.
As quoted in the press release:
The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
Click here to read the GenSpera Inc. (OTCQB:GNSZ) press release